Smith & Nephew plc (LON:SN - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,056.25 ($13.64) and traded as high as GBX 1,103.50 ($14.25). Smith & Nephew shares last traded at GBX 1,088.50 ($14.06), with a volume of 1,242,435 shares trading hands.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,180 ($15.24) price objective on shares of Smith & Nephew in a research note on Tuesday, January 14th.
View Our Latest Report on SN
Smith & Nephew Stock Performance
The firm's 50-day moving average price is GBX 1,061.24 and its 200-day moving average price is GBX 1,054.15. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The stock has a market cap of £11.89 billion, a P/E ratio of 39.06, a PEG ratio of 0.46 and a beta of 0.62.
Smith & Nephew Increases Dividend
The company also recently declared a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be paid a dividend of $0.23 per share. The ex-dividend date is Thursday, March 27th. This is a positive change from Smith & Nephew's previous dividend of $0.14. This represents a yield of 1.61%. Smith & Nephew's dividend payout ratio is presently 104.41%.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
